Literature DB >> 29214548

First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study.

Manuel Rubio-Rivas1, Xavier Corbella2,3, Melany Pestaña-Fernández2, Carles Tolosa-Vilella4, Alfredo Guillen-Del Castillo5, Dolores Colunga-Argüelles6, Luis Trapiella-Martínez7, Nerea Iniesta-Arandia8, María Jesús Castillo-Palma9, Luis Sáez-Comet10, María Victoria Egurbide-Arberas11, Norberto Ortego-Centeno12, Mayka Freire13, Jose Antonio Vargas-Hitos14, Juan José Ríos-Blanco15, Jose Antonio Todolí-Parra16, Mónica Rodríguez-Carballeira17, Adela Marín-Ballvé18, Pablo Segovia-Alonso19, Xavier Pla-Salas20, Ana Belén Madroñero-Vuelta21, Manuel Ruiz-Muñoz22, Vicent Fonollosa-Pla5, Carmen Pilar Simeón-Aznar5, E Callejas Moraga, E Calvo, C Carbonell, M J Castillo, A J Chamorro, D Colunga, X Corbella, M V Egurbide, G Espinosa, V Fonollosa, M Freire, F J García Hernández, R González León, A Guillén Del Castillo, N Iniesta, R Lorenzo, A B Madroñero, B Marí, A Marín, N Ortego-Centeno, M Pérez Conesa, M Pestaña, X Pla, J J Ríos Blanco, M Rodríguez Carballeira, M Rubio Rivas, M Ruiz Muñoz, L Sáez Comet, P Segovia, C P Simeón, A Soto, E Tarí, J A Todolí, C Tolosa, L Trapiella, J A Vargas Hitos, G Verdejo.   

Abstract

The objective of the study is to determine the importance of the mode of onset as prognostic factor in systemic sclerosis (SSc). Data were collected from the Spanish Scleroderma Registry (RESCLE), a nationwide retrospective multicenter database created in 2006. As first symptom, we included Raynaud's phenomenon (RP), cutaneous sclerosis, arthralgia/arthritis, puffy hands, interstitial lung disease (ILD), pulmonary arterial hypertension (PAH), and digestive hypomotility. A total of 1625 patients were recruited. One thousand three hundred forty-two patients (83%) presented with RP as first symptom and 283 patients (17%) did not. Survival from first symptom in those patients with RP mode of onset was higher at any time than those with onset as non-Raynaud's phenomenon: 97 vs. 90% at 5 years, 93 vs. 82% at 10 years, 83 vs. 62% at 20 years, and 71 vs. 50% at 30 years (p < 0.001). In multivariate analysis, factors related to mortality were older age at onset, male gender, dcSSc subset, ILD, PAH, scleroderma renal crisis (SRC), heart involvement, and the mode of onset with non-Raynaud's phenomenon, especially in the form of puffy hands or pulmonary involvement. The mode of onset should be considered an independent prognostic factor in systemic sclerosis and, in particular, patients who initially present with non-Raynaud's phenomenon may be considered of poor prognosis.

Entities:  

Keywords:  Onset; Prognosis; Raynaud; Scleroderma; Systemic sclerosis

Mesh:

Year:  2017        PMID: 29214548     DOI: 10.1007/s10067-017-3936-7

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  14 in total

Review 1.  Real-world evidence in rheumatic diseases: relevance and lessons learnt.

Authors:  Durga Prasanna Misra; Vikas Agarwal
Journal:  Rheumatol Int       Date:  2019-02-06       Impact factor: 2.631

2.  Immunotherapy of systemic sclerosis.

Authors:  Christina G Katsiari; Theodora Simopoulou; Ioannis Alexiou; Lazaros I Sakkas
Journal:  Hum Vaccin Immunother       Date:  2018-07-16       Impact factor: 3.452

3.  Transforming growth factor beta isoforms and TGF-βR1 and TGF-βR2 expression in systemic sclerosis patients.

Authors:  José Alvaro Lomelí-Nieto; José Francisco Muñoz-Valle; Christian Johana Baños-Hernández; José Eduardo Navarro-Zarza; Juliana Marisol Godínez-Rubí; Samuel García-Arellano; María Guadalupe Ramírez-Dueñas; Isela Parra-Rojas; Arisbeth Villanueva-Pérez; Jorge Hernández-Bello
Journal:  Clin Exp Med       Date:  2022-05-29       Impact factor: 3.984

4.  Increased risk of mortality in systemic sclerosis-associated pulmonary hypertension: a systemic review and meta-analysis.

Authors:  Anji Xiong; Qingting Liu; Jiaxun Zhong; Yuzi Cao; Qilang Xiang; Ziyi Hu; Shifeng Zhou; Zhuoyao Song; Huini Chen; Yan Zhang; Hongxu Cui; Shiquan Shuai
Journal:  Adv Rheumatol       Date:  2022-03-30

5.  Mortality and morbidity in scleroderma renal crisis: A systematic literature review.

Authors:  Hyein Kim; Frédéric Lefebvre; Sabrina Hoa; Marie Hudson
Journal:  J Scleroderma Relat Disord       Date:  2020-06-01

6.  Efficacy of subcutaneous tocilizumab in patients with rheumatoid arthritis and systemic sclerosis overlap syndrome: a report of two cases and review of the literature.

Authors:  Hiroki Wakabayashi; Hitoshi Kino; Makoto Kondo; Keiichi Yamanaka; Masahiro Hasegawa; Akihiro Sudo
Journal:  BMC Rheumatol       Date:  2019-04-24

7.  Generation of a novel CD30+ B cell subset producing GM-CSF and its possible link to the pathogenesis of systemic sclerosis.

Authors:  K Higashioka; Y Kikushige; M Ayano; Y Kimoto; H Mitoma; M Kikukawa; M Akahoshi; Y Arinobu; T Horiuchi; K Akashi; H Niiro
Journal:  Clin Exp Immunol       Date:  2020-07-14       Impact factor: 4.330

8.  Survival rate, causes of death, and risk factors in systemic sclerosis: a large cohort study.

Authors:  Xue Li; Yu-Quan Qian; Na Liu; Rong Mu; Yu Zuo; Guo-Chun Wang; Yuan Jia; Zhan-Guo Li
Journal:  Clin Rheumatol       Date:  2018-09-18       Impact factor: 2.980

Review 9.  The Relationship between Pulmonary Damage and Peripheral Vascular Manifestations in Systemic Sclerosis Patients.

Authors:  Barbara Ruaro; Marco Confalonieri; Francesco Salton; Barbara Wade; Elisa Baratella; Pietro Geri; Paola Confalonieri; Metka Kodric; Marco Biolo; Cosimo Bruni
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-23

Review 10.  Idiopathic pulmonary fibrosis and systemic sclerosis: pathogenic mechanisms and therapeutic interventions.

Authors:  Hamid Mattoo; Shiv Pillai
Journal:  Cell Mol Life Sci       Date:  2021-06-18       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.